(thirdQuint)Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies.

 This is a dose-finding, open-label, single agent study of RX-3117.

 Once the maximum tolerated dose is identified additional subjects will be treated in a dose expansion followed by a 2-stage Phase 2 study.

 Subjects will be treated for up to 8 cycles of therapy.

 A cycle will be 4 weeks.

 RX-3117 dosing will be 3 times each week for 3 weeks follow by 1 week off treatment.

 All subjects will be followed for at least 30 days after the last dose of RX-3117.

.

 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies@highlight

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1).

 The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).

